FITC Anti-DR4 antibody [DR-4-02] (ab59047)
Key features and details
- FITC Mouse monoclonal [DR-4-02] to DR4
- Reacts with: Human
- Conjugation: FITC. Ex: 493nm, Em: 528nm
- Isotype: IgG1
Overview
-
Product name
FITC Anti-DR4 antibody [DR-4-02]
See all DR4 primary antibodies -
Description
FITC Mouse monoclonal [DR-4-02] to DR4 -
Host species
Mouse -
Conjugation
FITC. Ex: 493nm, Em: 528nm -
Specificity
The antibody recognizes TRAIL R1 (DR4), a human death receptor 4 (468 amino acids) expressed in most human tissues (spleen, peripheral blood leucocytes, thymus) and in a variety of tumour derived cell lines. -
Species reactivity
Reacts with: Human -
Immunogen
Fusion protein (Human) containing the extracellular part of DR4 and the constant part of the heavy chain of human IgG1.
-
General notes
Do not use after expiration date stamped on vial label. Short term exposure to room temperature should not affect the quality of the reagent. However, if reagent is stored under any conditions other than those specified, the conditions must be verified by the user.Soluble antibody blocks DR4 receptor against TRAIL induced apoptosis. Plastic immobilized antibody induces apoptosis in sensitive cells.
The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC and adjusted for direct use. No reconstitution is necessary.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. -
Storage buffer
pH: 7.4
Preservative: 0.097% Sodium azide
Constituent: 0.2% BSA
0.2% high grade protease free BSA -
Concentration information loading... -
Purity
Size exclusion -
Purification notes
The antibody was >95% pure prior to conjugation as determined from SDS-PAGE (by protein A affinity chromatography). -
Primary antibody notes
Soluble antibody blocks DR4 receptor against TRAIL induced apoptosis. Plastic immobilized antibody induces apoptosis in sensitive cells. -
Clonality
Monoclonal -
Clone number
DR-4-02 -
Isotype
IgG1 -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Recombinant Protein
Target
-
Function
Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B. -
Tissue specificity
Widely expressed. High levels are found in spleen, peripheral blood leukocytes, small intestine and thymus, but also in K562 erythroleukemia cells, MCF7 breast carcinoma cells and activated T-cells. -
Sequence similarities
Contains 1 death domain.
Contains 3 TNFR-Cys repeats. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 8797 Human
- Omim: 603611 Human
- SwissProt: O00220 Human
- Unigene: 213467 Human
- Unigene: 591834 Human
-
Alternative names
- Apo2 antibody
- CD261 antibody
- Cytotoxic TRAIL receptor antibody
see all
Protocols
References (4)
ab59047 has been referenced in 4 publications.
- Strekalova E et al. Preclinical Breast Cancer Models to Investigate Metabolic Priming by Methionine Restriction. Methods Mol Biol 1866:61-73 (2019). PubMed: 30725408
- Piggott L et al. Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP. Clin Cancer Res 24:2452-2463 (2018). PubMed: 29363524
- Nesterenko I et al. Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomas. PLoS One 7:e49219 (2012). Flow Cyt ; Human . PubMed: 23145127
- Fan S et al. Scatter factor protects tumor cells against apoptosis caused by TRAIL. Anticancer Drugs 21:10-24 (2010). IP . PubMed: 19823077
